A Phase I/II Study of MK-3475 (SCH900475) in Combination With Chemotherapy or Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma

Trial Profile

A Phase I/II Study of MK-3475 (SCH900475) in Combination With Chemotherapy or Immunotherapy in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Carcinoma

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Pembrolizumab (Primary) ; Bevacizumab; Carboplatin; Erlotinib; Gefitinib; Ipilimumab; Paclitaxel; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Acronyms KEYNOTE-021
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 29 Sep 2017 According to a Merck AG media release, data will be presented at the 18th World Conference on Lung Cancer (WCLC).
    • 08 Sep 2017 Results published in a Merck AG Media Release.
    • 08 Sep 2017 According to a Merck AG media release, five months data from cohort G of this study will be presented at ESMO 2017 Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top